Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hero Technologies Inc. (HENC)
Dover, DE, US
Hero Technologies Inc. functions as a nascent enterprise within the cannabis industry. Its primary focus is on the BlackBox, a proprietary aeroponic cannabis cultivation system. This cutting-edge system is engineered to create optimal growing conditions, thereby significantly boosting photosynthesis and enabling the development of robust flowering plants, which ultimately leads to more efficient harvests. Additionally, the company intends to expand its operations to include cannabis genetic engineering and providing farmland to support the full scope of medical and recreational cannabis activities, from cultivation and production to distribution, packaging, and retail operations, including dispensaries. The company was established in 2004 and is headquartered in Dover, Delaware.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.31% | -99.85% | -99.80% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-100.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+85.0% ★ Q3'23: -100.0% (vs Q3'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-101.4% Q3'23: +4,313.0% (vs Q3'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.1% Q3'23: +21.1% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.43× Q3'23: 0.00× (vs Q3'22)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ali Tabassi | Chief Technology Officer | — | male |
| Destiny Aigbe | Chief Executive Officer & Director | — | male |
| Thandi Ncube | Corporate Development Manager | — | — |
| Timothy E. Dunleavy | Vice President of Finance | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HENC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
